This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.
Roivant Sciences Ltd. (NYSE: ROIV) announced that it will present topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the European Respiratory Society International Congress 2026. The presentation is scheduled for Tuesday, September 8, 2026, at 12:15 CEST (6:15 a.m. ET). Marc Humbert, MD, PhD, will deliver the talk.
According to the announcement, Roivant will also host an investor call and webcast at 8:00 a.m. ET on the same day. Access details and an archived webcast will be available in the Investors Events and Presentations section of the company website. The company stated that the presentation will cover the topline results of the Phase 2 PHocus study, which evaluates mosliciguat for the treatment of PH-ILD.
Roivant Sciences is a biopharmaceutical company that develops and commercializes medicines. The company operates through various subsidiaries and focuses on treating serious diseases. The PHocus study is part of the company’s ongoing clinical development efforts. Mosliciguat is being investigated for its potential to address pulmonary hypertension associated with interstitial lung disease. Pulmonary hypertension is a condition where the blood vessels in the lungs become narrowed or stiff, forcing the right side of the heart to work harder to push blood through. Interstitial lung disease is a group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, making it harder for oxygen to pass into the blood.
The company noted that recent insider activity recorded 1,400,000 shares sold and no purchases. This activity was reported by a market data platform and adds cautionary context to the scheduled clinical readout. The active shelf and eventual topline details were identified as key items for investors to monitor.
Roivant Sciences has a history of clinical and regulatory milestones. In August 2026, the company reported that LISRAYA received FDA approval for adults with dermatomyositis. The company also presented Phase 3 VALOR skin-specific outcomes, which showed improved response versus placebo. Additionally, the BEACON+ study enrolled first patients in a Phase 3 cutaneous sarcoidosis study. The company’s most recent earnings report indicated a net loss of $290.6 million and revenue of $1.4 million for the quarter.
The presentation at the ERS Congress 2026 is a significant event for Roivant Sciences as it provides data on a potential new treatment indication. Investors will be watching for the topline results to assess the efficacy and safety profile of mosliciguat in the PH-ILD population. The company’s ability to advance its clinical pipeline is critical for its long-term growth strategy. The upcoming investor call will likely provide further details on the study design, patient demographics, and statistical significance of the results.
Roivant Sciences continues to expand its portfolio of therapeutic candidates. The company’s focus on rare and serious diseases positions it in a specialized segment of the biopharmaceutical industry. The results of the PHocus study could influence the company’s future development plans and regulatory submissions. The company has not disclosed the specific endpoints or statistical thresholds for the PHocus study in this announcement.
The market reaction to the announcement will depend on the perceived value of the clinical data and the company’s overall financial position. The recent insider selling activity may signal internal perspectives on valuation, although such transactions can also be part of pre-planned trading programs. Investors should review the full presentation and investor call materials for comprehensive insights.
Roivant Sciences remains committed to advancing its clinical programs. The company’s website and investor relations materials provide additional information on its pipeline and corporate strategy. The ERS Congress 2026 presentation is a key milestone in the development of mosliciguat.
Sources
